PMID- 35708048
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20221215
LR  - 20221215
IS  - 1827-1669 (Electronic)
IS  - 0026-4806 (Linking)
VI  - 113
IP  - 5
DP  - 2022 Oct
TI  - Morniflumate in the treatment of upper airways affections in adults: a review and 
      meta-analysis.
PG  - 853-863
LID - 10.23736/S0026-4806.22.08200-3 [doi]
AB  - INTRODUCTION: We compared, by a meta-analytic process, the antipyretic and 
      symptomatic activity, and the safety profile of morniflumate (ATC code: M01AX22) 
      with those of other commonly used non-steroidal anti-inflammatory drugs (NSAIDs) 
      in acute ear, nose and throat (ENT) diseases. EVIDENCE ACQUISITION: Our search 
      strategy was performed in various database, included Google Scholar, PubMed and 
      Embase, the key word was "morniflumate". Interventional studies in adults with 
      ENT or lower airway inflammatory diseases were compared in a meta-analysis for 
      the number of symptom-free and fever-free patients at day 3 of therapy, and of 
      drug interruptions due to adverse events (AEs). For symptoms, we included only 
      studies on ENT inflammatory diseases; for fever and AEs, we also considered 
      studies on lower airway inflammatory diseases. Of 33 studies retrieved, 8 (24.2%) 
      met the inclusion criteria and compared morniflumate to placebo, nimesulide, 
      paracetamol and other NSAIDs. EVIDENCE SYNTHESIS: On day 3, the number of 
      symptom-free patients was significantly higher with morniflumate vs placebo and 
      nimesulide (+20% and +30%, respectively) and similar to the other comparators. 
      The number of fever-free patients significantly increased (up to 70%) with 
      morniflumate vs all comparators except paracetamol (similar). No difference was 
      found in the number of AE-related interruptions. CONCLUSIONS: morniflumate showed 
      good antipyretic and symptomatic activity and a short-term safety profile at 
      least comparable to that of other NSAIDs.
FAU - Paleari, Davide
AU  - Paleari D
AD  - Medical Department, Chiesi Italia S.p.A, Parma, Italy - d.paleari@chiesi.com.
FAU - Cavalieri, Luca
AU  - Cavalieri L
AD  - Medical Department, Chiesi Italia S.p.A, Parma, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220614
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
SB  - IM
EDAT- 2022/06/17 06:00
MHDA- 2022/06/17 06:01
CRDT- 2022/06/16 05:10
PHST- 2022/06/17 06:00 [pubmed]
PHST- 2022/06/17 06:01 [medline]
PHST- 2022/06/16 05:10 [entrez]
AID - S0026-4806.22.08200-3 [pii]
AID - 10.23736/S0026-4806.22.08200-3 [doi]
PST - ppublish
SO  - Minerva Med. 2022 Oct;113(5):853-863. doi: 10.23736/S0026-4806.22.08200-3. Epub 
      2022 Jun 14.